CERo Therapeutics (NASDAQ: CERO) Advances Phase 1 CER-1236 Trial with Third Patient Dosed

April 14, 2026

Key Developments CERo Therapeutics (NASDAQ: CERO) has announced a significant advancement in its Phase 1 clinical trial for CER-1236 with the dosing of the third patient in Cohort 2. This milestone reflects the company’s progress in evaluating the safety and efficacy of its novel therapeutic compound. The ongoing trial is designed to expand its patient base to include individuals with myelodysplastic syndrome (MDS) and myelofibrosis (MF), two serious bone marrow…

Read More >>